Search results: Sage Journals

Open accessReview articleFirst published 2023

Precision oncology with selective RET inhibitor selpercatinib in RET -rearranged cancers

Mohamed A. Gouda, Vivek Subbiah

Therapeutic Advances in Medical Oncology

Restricted accessReview articleFirst published March, 2023

An overview of the role of selpercatinib and pralsetinib in RET-fusion-positive non-small cell lung cancer (NSCLC)

Vanessa Quang Nguyen, Marc Geirnaert

Journal of Oncology Pharmacy Practice

Restricted accessResearch articleFirst published June, 2026

A Novel Approach to Targeting DLL3 with Tarlatamab in a Patient with Medullary Thyroid Carcinoma after Progression on Selpercatinib

Thomas J. Roberts, Catherine B. Meador, Alexander D. Fuld [...]

Thyroid®

Restricted accessCase reportFirst published December, 2025

Selpercatinib plus cemiplimab in RET positive medullary thyroid cancer patient with skin cancers

Laura Deborah Locati, Federica Puce, Vito Amoroso [...]

Tumori Journal

Restricted accessResearch articleFirst published March 16, 2023

A Case Report of Poor Response to Selpercatinib in the Presence of a 632_633 RET Deletion

Ayanthi Wijewardene, Karine Bastard, Bin Wang [...]

VideoEndocrinology™

Restricted accessCase reportFirst published 2026

Central nervous system effectiveness of selpercatinib retreatment in heavily pretreated NSCLC patient with RET rearrangement: A case report

Margherita Agostini, Samuele Compagno, Francesca Sperandi [...]

Tumori Journal

Restricted accessResearch articleFirst published June 28, 2022

Response to Selpercatinib in an Adolescent with RET Fusion-Positive Papillary Thyroid Carcinoma with Extensive Intracranial and Pulmonary Metastases

Priya Mahajan, Rajkumar Venkatramani

VideoEndocrinology™

Open accessResearch articleFirst published 2021

Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program

Oliver Illini, Maximilian Johannes Hochmair, Hannah Fabikan [...]

Therapeutic Advances in Medical Oncology

Open accessResearch articleFirst published 2022

Efficacy and safety of selpercatinib in Chinese patients with advanced RET -altered thyroid cancers: results from the phase II LIBRETTO-321 study

Xiangqian Zheng, Qinghai Ji, Yuping Sun [...]

Therapeutic Advances in Medical Oncology

Open accessResearch articleFirst published 2023

Patient-reported outcomes following selpercatinib treatment in Chinese patients with advanced RET fusion-positive non-small-cell lung cancer and thyroid cancer,and RET -mutant medullary thyroid cancer in the phase II LIBRETTO-321 trial

Shun Lu, Xiangqian Zheng, Yuping Sun [...]

Therapeutic Advances in Medical Oncology

Open accessReview articleFirst published 2023

Precision oncology with selective RET inhibitor selpercatinib in RET -rearranged cancers

Mohamed A. Gouda, Vivek Subbiah

Therapeutic Advances in Medical Oncology

Restricted accessReview articleFirst published March, 2023

An overview of the role of selpercatinib and pralsetinib in RET-fusion-positive non-small cell lung cancer (NSCLC)

Vanessa Quang Nguyen, Marc Geirnaert

Journal of Oncology Pharmacy Practice

Restricted accessResearch articleFirst published June, 2026

A Novel Approach to Targeting DLL3 with Tarlatamab in a Patient with Medullary Thyroid Carcinoma after Progression on Selpercatinib

Thomas J. Roberts, Catherine B. Meador, Alexander D. Fuld [...]

Thyroid®

Restricted accessCase reportFirst published December, 2025

Selpercatinib plus cemiplimab in RET positive medullary thyroid cancer patient with skin cancers

Laura Deborah Locati, Federica Puce, Vito Amoroso [...]

Tumori Journal

Restricted accessResearch articleFirst published March 16, 2023

A Case Report of Poor Response to Selpercatinib in the Presence of a 632_633 RET Deletion

Ayanthi Wijewardene, Karine Bastard, Bin Wang [...]

VideoEndocrinology™

Restricted accessCase reportFirst published 2026

Central nervous system effectiveness of selpercatinib retreatment in heavily pretreated NSCLC patient with RET rearrangement: A case report

Margherita Agostini, Samuele Compagno, Francesca Sperandi [...]

Tumori Journal

Restricted accessResearch articleFirst published June 28, 2022

Response to Selpercatinib in an Adolescent with RET Fusion-Positive Papillary Thyroid Carcinoma with Extensive Intracranial and Pulmonary Metastases

Priya Mahajan, Rajkumar Venkatramani

VideoEndocrinology™

Open accessResearch articleFirst published 2021

Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program

Oliver Illini, Maximilian Johannes Hochmair, Hannah Fabikan [...]

Therapeutic Advances in Medical Oncology

Open accessResearch articleFirst published 2022

Efficacy and safety of selpercatinib in Chinese patients with advanced RET -altered thyroid cancers: results from the phase II LIBRETTO-321 study

Xiangqian Zheng, Qinghai Ji, Yuping Sun [...]

Therapeutic Advances in Medical Oncology

Open accessResearch articleFirst published 2023

Patient-reported outcomes following selpercatinib treatment in Chinese patients with advanced RET fusion-positive non-small-cell lung cancer and thyroid cancer,and RET -mutant medullary thyroid cancer in the phase II LIBRETTO-321 trial

Shun Lu, Xiangqian Zheng, Yuping Sun [...]

Therapeutic Advances in Medical Oncology